Overview
Lingzhi Hong is a Hematologist Oncology provider practicing medicine in Houston, Texas.
Dr. Hong is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and PIK3CA-Related Overgrowth Spectrum.
She is actively involved in clinical research, co-authoring 56 peer reviewed articles.
Specialties
Licenses
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Baylor College Of Medicine
Dr. Mothaffar F. Rimawi is a board-certified medical oncologist specializing in breast cancer care and research. He is Professor at the Department of Medicine, Section of Hematology and Oncology at Baylor College of Medicine. Dr. Rimawi is also Executive Medical Director & Associate Director of Clinical Affairs and Co-Leader of the Breast Cancer Program at BCM’s Dan L Duncan Comprehensive Cancer Center. Additionally, he serves as Chief of the Oncology Service Line at St Luke's Health in Houston.Dr. Rimawi’s professional interests include: the diagnosis, treatment and management of breast cancer; clinical trials in breast cancer; neoadjuvant therapy; targeted therapy and biomarkers in breast cancer; treatment resistance to ER and HER2-targeted therapies in breast cancer; locally advanced breast cancer; and breast disease and cancer.Dr. Rimawi received his medical degree from the University of Jordan in Amman, Jordan. He completed his residency in Internal Medicine and fellowships in Medical Oncology and Hematology and Breast Cancer at BCM. Dr. Rimawi holds certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine. He is a member of the American College of Physicians, American Society of Clinical Oncology and the American Medical Association.In addition to English, Dr. Rimawi speaks Arabic. Dr. Rimawi is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast. Dr. Rimawi is currently accepting new patients.
Kelsey-Seybold Clinic
Sumaira Shafi is a Hematologist Oncology specialist and a Hematologist practicing medicine in Spring, Texas. Dr. Shafi is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.
MD Anderson
Dan Zhao is a Hematologist Oncology specialist and an Oncologist practicing medicine in Houston, Texas. Dr. Zhao is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, and Pancreatic Ductal Adenocarcinoma.
Frequently Asked Questions about Dr. Lingzhi Y. Hong
How do I make an appointment with Dr. Lingzhi Y. Hong?
You can book an appointment with Dr. Lingzhi Y. Hong by calling their office at 713-792-6363. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Lingzhi Y. Hong a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lingzhi Y. Hong is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Lingzhi Y. Hong specialize in?
While Dr. Lingzhi Y. Hong is a Hematology Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.
Does Dr. Lingzhi Y. Hong participate in research or clinical trials?
Yes. Dr. Lingzhi Y. Hong has published 56 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Lingzhi Y. Hong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Lung AdenocarcinomaDr. Hong isAdvanced. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Hong isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Experienced
- Ataxia-TelangiectasiaDr. Hong isExperienced. Learn about Ataxia-Telangiectasia.
- EGFR Positive Lung CancerDr. Hong isExperienced. Learn about EGFR Positive Lung Cancer.
- PIK3CA-Related Overgrowth SpectrumDr. Hong isExperienced. Learn about PIK3CA-Related Overgrowth Spectrum.
- Squamous Cell Lung CarcinomaDr. Hong isExperienced. Learn about Squamous Cell Lung Carcinoma.